Drug Profile
Research programme: beta-catenin/lef-1 inhibitors - Novartis/University of Cologne
Alternative Names: CGP049090; PKF-115584Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Novartis; University of Cologne
- Class Small molecules
- Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Germany
- 21 Apr 2010 Pharmacodynamics data from a preclinical trial in Chronic lymphocytic leukaemia presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
- 16 Apr 2008 Preclinical pharmacodynamics data presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)